-

 

Chronic Non-Communicable Diseases and PFAS: Implications for Prevention, Treatment, and Management of Hypertension

Abstract

Per- and polyfluoroalkyl substances (PFAS) have emerged as critical environmental contaminants implicated in the rise of chronic non-communicable diseases (NCDs) worldwide. Their persistence, bioaccumulation, and interference with endocrine and vascular systems have made them a hidden but significant contributor to hypertension and cardiovascular disorders. This paper explores the intersection between PFAS exposure and hypertension, emphasizing the biological mechanisms, public health consequences, and socio-economic implications. It further outlines integrated strategies for prevention, treatment, and management, with attention to policy design, clinical adaptation, and environmental justice, particularly in developing regions such as Africa.

1. Introduction

Hypertension is one of the most prevalent chronic non-communicable diseases globally, affecting over 1.28 billion adults, two-thirds of whom reside in low- and middle-income countries (WHO, 2023). Traditionally linked to diet, genetics, and lifestyle, hypertension is now increasingly recognized as an environmentally influenced condition. Among emerging environmental contributors, PFAS—a large class of synthetic fluorinated chemicals—have gained attention due to their persistence, toxicity, and potential to disrupt cardiovascular homeostasis.

PFAS are widely used in industrial and consumer products including non-stick cookware, food packaging, waterproof fabrics, and firefighting foams. Their exceptional chemical stability allows them to persist in soil, water, and biological tissues for decades, earning them the label “forever chemicals.” Studies have demonstrated that PFAS can accumulate in blood, kidneys, and liver, where they disrupt lipid metabolism, hormone regulation, and vascular function—all central to the pathophysiology of hypertension.

As countries, particularly in the Global South, face dual challenges of industrialization and weak environmental governance, the threat of PFAS-induced hypertension underscores a growing intersection between pollution, poverty, and chronic disease. Addressing this requires a new framework that unites environmental health, clinical medicine, and public policy.

2. PFAS Exposure and the Pathophysiology of Hypertension

2.1 Exposure Pathways

PFAS exposure occurs through multiple interconnected routes:

  • Contaminated drinking water: Industrial discharges, landfill leachate, and use of PFAS-containing firefighting foams.

  • Food contamination: Bioaccumulation in fish, livestock, and crops irrigated with polluted water.

  • Inhalation and dust ingestion: Common in indoor environments with treated carpets, furniture, or electronics.

  • Dermal contact and cosmetics: Lotions, sunscreens, and make-up frequently contain PFAS compounds.

  • Transplacental and lactational transfer: Exposure begins prenatally, affecting cardiovascular development in fetuses and infants.

2.2 Mechanisms of PFAS-Induced Hypertension

The biological mechanisms linking PFAS exposure to hypertension are complex and multifactorial:

  1. Endocrine Disruption: PFAS interfere with the renin-angiotensin-aldosterone system (RAAS), leading to altered vascular tone and sodium retention.

  2. Oxidative Stress: PFAS induce reactive oxygen species (ROS) that damage vascular endothelium and reduce nitric oxide bioavailability, impairing vasodilation.

  3. Thyroid Dysfunction: PFAS reduce circulating thyroid hormones, slowing metabolism and promoting hyperlipidemia—a risk factor for vascular stiffness.

  4. Renal Effects: PFAS accumulate in renal tissue, diminishing glomerular filtration rate (GFR) and altering electrolyte balance.

  5. Inflammatory Pathways: Elevated interleukins and C-reactive protein levels have been observed in PFAS-exposed populations, indicating chronic low-grade inflammation that raises blood pressure.

3. Epidemiological Evidence Linking PFAS and Hypertension

3.1 Global Evidence

  • U.S. NHANES Studies (2003–2018): Individuals in the highest quartile of PFOS exposure showed a 22–30% higher risk of hypertension after adjusting for BMI and socioeconomic factors (Jain, 2021).

  • European Cohort Studies: The C8 Health Project in Italy and the U.K. linked long-term PFAS exposure to arterial stiffness, dyslipidemia, and early-onset hypertension.

  • Asian Populations: In China, higher serum PFAS levels were associated with elevated systolic blood pressure and increased markers of oxidative stress.

3.2 African Context

In Africa, where industrial monitoring remains limited, PFAS contamination is emerging as a silent crisis. Studies in Kenya, Nigeria, and South Africa have reported PFAS residues in rivers, boreholes, and fish tissue near industrial areas. Informal recycling of electronic waste and unregulated manufacturing exacerbate exposure risks.
Given the rising prevalence of hypertension in sub-Saharan Africa—estimated to affect over 35% of adults—PFAS exposure represents an unseen environmental driver that amplifies existing health inequities. Women, children, and workers in informal sectors are particularly at risk.

4. PFAS, Chronic Disease, and the Hypertension Nexus

PFAS act as chemical amplifiers of traditional NCD risk factors such as obesity, poor diet, and sedentary lifestyle. Their chronic presence in the bloodstream contributes to:

  • Dyslipidemia: PFAS elevate total cholesterol and LDL levels, accelerating atherosclerosis.

  • Insulin Resistance: By disrupting glucose metabolism, PFAS increase the risk of metabolic syndrome—a precursor to hypertension.

  • Vascular Remodeling: Persistent exposure thickens arterial walls and increases peripheral resistance.

  • Cardiac Remodeling: Animal studies demonstrate hypertrophy and myocardial fibrosis after prolonged PFAS exposure.

These mechanisms position PFAS as a modifiable environmental determinant of cardiovascular disease that interacts synergistically with other social and biological risks.

5. Implications for Prevention, Treatment, and Management

5.1 Prevention

Effective prevention demands a dual approach—environmental and biomedical.

Environmental Measures:

  • Strengthen regulation of PFAS emissions and enforce discharge limits in industries.

  • Ban PFAS-containing materials in food packaging, firefighting foams, and cosmetics.

  • Invest in water treatment technologies such as granular activated carbon (GAC), ion exchange resins, and reverse osmosis for contaminated communities.

Public Health Strategies:

  • Establish PFAS exposure registries and geographic mapping of high-risk zones.

  • Conduct community education on safe food handling, water sources, and consumer awareness.

  • Integrate PFAS awareness into non-communicable disease prevention programs.

5.2 Treatment Implications

Clinicians treating hypertension must begin to recognize PFAS exposure as a potential contributing factor:

  • Clinical Screening: Assess patient exposure history—occupation, residence near industrial areas, and use of PFAS-containing products.

  • Pharmacological Considerations: PFAS may alter hepatic enzyme activity, affecting metabolism of antihypertensive drugs like beta-blockers and ACE inhibitors.

  • Antioxidant Support: Dietary antioxidants (vitamin C, E, polyphenols) may mitigate oxidative stress.

  • Renal Monitoring: Regular evaluation of kidney function for PFAS-exposed individuals can guide therapeutic decisions.

5.3 Long-Term Management

Long-term management should incorporate integrated chronic care models:

  • Include environmental determinants in national hypertension guidelines.

  • Promote community-based screening programs in industrial and peri-urban areas.

  • Encourage multi-sectoral collaboration between environmental scientists, clinicians, and policymakers.

  • Integrate lifestyle modification programs with PFAS risk reduction strategies—reducing processed food intake and ensuring access to clean water.

6. Policy, Governance, and Ethical Dimensions

6.1 Policy Integration

PFAS management should be embedded in national non-communicable disease action plans and environmental protection laws. Environmental exposure must be acknowledged as a social determinant of health.

6.2 Legal Accountability

Governments should apply the polluter-pays principle to industries that release PFAS. Liability laws must compel cleanup, compensation, and preventive innovation.

6.3 Surveillance and Data Systems

  • Establish PFAS biomonitoring laboratories in national public health institutes.

  • Collect and integrate PFAS exposure data with hypertension and cardiovascular disease registries.

  • Train health workers to identify and report environmental exposure indicators.

6.4 Ethical and Equity Considerations

PFAS contamination disproportionately affects marginalized populations—those with the least capacity to mitigate risk. Policies must therefore align with environmental justice principles, ensuring equitable access to safe water, healthcare, and information.

7. Global and Regional Collaboration

Given PFAS’s transboundary persistence, no single nation can tackle it alone. Global cooperation through the Stockholm Convention on Persistent Organic Pollutants and regional alliances such as the African Chemicals Management Partnership (ACMP) can:

  • Harmonize regulatory standards.

  • Facilitate technology transfer for PFAS remediation.

  • Strengthen capacity for chemical analysis and public health surveillance.

UNEP’s 2023 Global PFAS Action Plan provides a blueprint for phasing out hazardous PFAS compounds and fostering PFAS-free innovation—a roadmap African states should urgently adopt.

8. Conclusion

PFAS exposure represents a critical but under-recognized driver of hypertension and chronic non-communicable disease. By altering vascular, endocrine, and metabolic systems, PFAS undermine global health efforts to control cardiovascular diseases.

A forward-looking policy response must integrate:

  1. Prevention: Through strict environmental regulation and community education.

  2. Treatment: Through clinician awareness, patient-centered management, and exposure screening.

  3. Management: Through cross-sectoral collaboration linking health, environment, and industry.

Mitigating PFAS-related hypertension is not merely a biomedical challenge—it is an environmental justice imperative. Protecting communities from PFAS will yield long-term dividends for cardiovascular health, healthcare costs, and sustainable development.

References

  1. Jain, R. (2021). Association between PFAS exposure and blood pressure in the U.S. population. Environmental Research, 200(2):111465.

  2. Shankar, A., Xiao, J., & Ducatman, A. (2012). Perfluoroalkyl chemicals and elevated serum uric acid in U.S. adults. Environmental Health Perspectives, 120(2), 155–160.

  3. Liu, C., et al. (2023). Perfluoroalkyl substances and vascular function: Mechanistic and epidemiological insights. Journal of Hypertension, 41(3), 345–357.

  4. WHO. (2023). Global Status Report on Noncommunicable Diseases 2023. Geneva: World Health Organization.

  5. ATSDR. (2021). Toxicological Profile for Perfluoroalkyl Substances. U.S. Department of Health and Human Services.

  6. UNEP. (2023). PFAS and Persistent Organic Pollutants: Global Status Report. United Nations Environment Programme.

  7. Nyambura, L. et al. (2024). Emerging PFAS contamination in urban rivers of Kenya. African Journal of Environmental Science, 19(2), 65–78.

  8. Grandjean, P., & Clapp, R. (2015). Perfluorinated alkyl substances: Emerging insights into health risks. New Solutions, 25(2), 147–163.

Comments

Post a Comment

Popular posts from this blog

-
  Impacts of Pit Latrine Waste on Early Puberty in Africa Introduction Across sub-Saharan Africa, pit latrines serve as the primary sanitation infrastructure for over 50% of urban populations and an even higher proportion in rural areas, providing a low-cost solution to the challenge of open defecation. These simple, often unlined pits collect human waste but pose significant risks to environmental and public health due to potential groundwater contamination. Emerging evidence suggests that chemical pollutants from pit latrines, particularly endocrine-disrupting chemicals (EDCs), may contribute to early puberty in children, especially girls, with far-reaching health, social, and educational consequences. Early puberty, defined as pubertal development before age 8 in girls or 9 in boys, is associated with increased risks of mental health disorders, reproductive health issues, and socioeconomic challenges, particularly in resource-constrained settings. In Africa, where sanitation inf...
Read more
-
  Health insurance affordability and the quality of life among low Socioeconomic Status (SES) individuals in Low- and Middle-Income Countries (LMICs)   Preamble: Whereas the right to health is a fundamental human right, it remains inaccessible to many, especially those of low socioeconomic status (SES) in low- and middle-income countries (LMICs); and whereas the affordability of health insurance is a critical factor that can enhance or impede access to necessary healthcare services; we recognize that the ability to obtain health insurance plays a pivotal role in determining the quality of life for individuals and families within these communities. Acknowledging that the lack of affordable health insurance options leads to a disproportionate burden of disease and financial hardship on low SES populations; and understanding that the provision of affordable health insurance is not only a matter of social justice but also an investment in the social and economic development ...
Read more
-
Child Health:  Dealing with Aflatoxins in Children’s Food Aflatoxins, produced primarily by Aspergillus flavus and A. parasiticus , are highly toxic and carcinogenic mycotoxins that contaminate key food crops in tropical and subtropical regions. In low- and middle-income countries (LMICs), especially across sub-Saharan Africa, chronic exposure to aflatoxins in staple foods poses grave health risks for children, including growth impairment, immunosuppression, developmental deficits, and increased vulnerability to infectious diseases. This paper explores the sources of aflatoxin contamination in children's food, its public health impacts, and proposes multisectoral policies and interventions to protect child health and nutrition, with a focus on evidence from Africa. 1. Introduction Aflatoxin contamination is one of the most pressing yet under-addressed food safety challenges affecting children in LMICs. Staple foods such as maize, sorghum, groundnuts, and dairy products are pro...
Read more